Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
AtlasXomics
AddedFeb 15, 2024
UpdatedJun 18, 2026
AtlasXomics

AtlasXomics

Series A

AtlasXomics: Pioneering spatial-omics sequencing in oncology, neurology, and aging.

HQ
New Haven, CT, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

AtlasXomics, founded to revolutionize spatial-omics sequencing, focuses on applications in oncology, neurology, and aging. The company offers a pioneering comprehensive spatial epigenome solution at cellular resolution, enabling detailed tissue analysis and identification of unique cell populations without bias. Their technology facilitates genome-wide mapping of cell populations for regulatory elements, uncovering essential mechanisms of tissue biology.

Notable affiliations include collaborations with leading research labs to map the epigenome in various tissues. Key achievements include the development of the first comprehensive spatial epigenome solution, significantly advancing the field of spatial biology. AtlasXomics' impact is evident in its contributions to understanding complex biological processes and potential therapeutic targets in critical areas such as cancer and neurodegenerative diseases.

AtlasXomics - Similar Companies

Spatial Genomics logo

Spatial Genomics

Stellaromics logo

Stellaromics

stellaromics.com

10x Genomics logo

10x Genomics

10xgenomics.com

XGenomes logo

XGenomes

xgenomes.com

Complete Omics logo

Complete Omics

completeomics.com

Rebus Biosystems logo

Rebus Biosystems

rebusbio.com

Singular Genomics logo

Singular Genomics

BioDatomics logo

BioDatomics

biodatomics.com

Cellanome logo

Cellanome

cellanome.com

EpiCypher logo

EpiCypher

epicypher.com

Epic-Bio logo

Epic-Bio

epic-bio.com

Genomenon logo

Genomenon

genomenon.com

Linus Biotechnology logo

Linus Biotechnology

linusbio.com

Eclipse Bioinnovations logo

Eclipse Bioinnovations

eclipsebio.com

Genome Insight logo

Genome Insight

AtlasXomics - Quick Facts

Who are AtlasXomics' competitors?

Companies similar to AtlasXomics include Spatial Genomics, Stellaromics, 10x Genomics and XGenomes.

When was AtlasXomics founded?

AtlasXomics was founded in 2020.

Where is AtlasXomics' headquarters located?

AtlasXomics' headquarters is located in New Haven, CT, US.

When was AtlasXomics' last funding round?

AtlasXomics' most recent funding round was for $3.9M (USD) in January 2022.

How much has AtlasXomics raised to-date?

As of Jan 6, 2022, AtlasXomics has raised a total of $5.7M (USD).

How many employees does AtlasXomics have?

AtlasXomics has 28 employees as of Feb 5, 2024.

AtlasXomics - Classification

Ownership
  • Venture Capital
Technology
  • AI
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Biotech
  • Sequencing
Tags
  • Data
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified